Loading
A phase 3 trial of Ziv-aflibercept in Uveal melanoma, run by Centre Hospitalier Universitaire de Nice, completed.
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma is a phase 3 interventional study registered as NCT03172299 by Centre Hospitalier Universitaire de Nice, with 57 participants recorded, started 2017-06-08 and reaching its primary completion in 2025-01-31. Interventions recorded: Aflibercept Injection, False injection. Conditions recorded: Ocular Melanoma.
Linked to the drug Ziv-aflibercept because the registry names it among its interventions and Uveal melanoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Uveal melanoma and the tag pipeline.
Shares Ziv-aflibercept and the tag pipeline.
Shares Ziv-aflibercept and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/